A double-blind, placebo-controlled, single-center, randomized, parallel-group clinical trial, efficacy of early intervention with Fluticason Furoate for patients with Japanese cedar pollinosis

INTERVENTION: Fluticasone furoate puff per nostril once a day 110 micro gram is administered from the beginning of pollinosis symptoms as a first‐line drug. 60mg of fexofenadine orally twice a day can be used as a backup drug. Placebo dreg puff per nostril once a day 110 micro gram is administered from the beginning of pollinosis symptoms as a first‐line drug. 60mg of fexofenadine orally twice a day can be used as a backup drug. CONDITION: Japanese cedar pollinosis PRIMARY OUTCOME: Total nasal symptom score (the sum of the severity score of 4 daily nasal symptoms; itchy nose, runny nose, stuffy nose, and sneezing. score range 0‐12.) SECONDARY OUTCOME: Rhinoconjunctivitis QOL Questionaire score(RQLQ,JRQLQ), The Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, Total ocular symptom score, INCLUSION CRITERIA: 1)A history of Japanese cedar pollinosis for at least one season before study entry. 2)Positive allergy skin test to Japanese cedar pollen or Japanese cedar pollen specific IgE RAST score >= class 2. 3)Mild / severe nasal symptoms with pollinosis in ARIA 4)Written informed consent is required.